Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MaaT013
Therapeutic Area: Immunology Product Name: MaaT013
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2020
Details:
Data from the Company’s compassionate use program with MaaT013 as a treatment in patients with intestinal acute Graft-versus-Host-Disease will be highlighted in an e-poster presentation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OSE-127
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Servier
Deal Size: $21.4 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 17, 2020
Details:
In December 2016, OSE Immunotherapeutics granted Servier a two-step option agreement to acquire the exclusive worldwide license to develop and commercialize OSE-127.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MaaT013
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Symbiosis Pharmaceutical Services LTD
Deal Size: $19.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 05, 2020
Details:
The funding will continue the clinical development of the company's current pipeline as well as the extension to other indications in oncology.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
